Figures & data
Table 1. Agents listed in the MICAD that target CA IX.
Table 2. PET and SPECT radionuclides combined with antibodies and antibody fragments for imaging CA IX.
Figure 1. Direct iodination of antibodies is typically achieved via the iodogen method to modify a tyrosine residueCitation47,Citation48.
Figure 2. Host-linker moieties that have been employed to indirectly radiolabel antibodies and antibody fragments targeting CA IX.
Figure 3. General synthetic methodology for the production of radiolabelled mAbs using desferrioxamine mesylate (desferal, Df) as the host-linker moietyCitation54.
Figure 4. Synthetic approach for the production of radiolabelled mAbs and mAb fragments using DOTA as the host-linker moiety.
Table 3. Properties of DOTA-CA IX mAb and mAb fragment conjugatesCitation12.
Table 4. T/B and T/M ratios for 111In-DOTA-cG250, 111In-DOTA-cG250-Fab and 111In-DOTA-cG250-F(ab′)2 in mice with HT-29 tumoursCitation12.
Table 5. The SUVmax of 89Zr-Df-cG250-F(ab′)2 and %ID/g of tissue taken from BALB nu/nu mice subcutaneously implanted with SCCNij3 cell xenograft tumours at 4 and 24 h p.i.Citation16.
Figure 5. Synthetic approach for the production of radiolabelled antibodies SIP format using p-SCN-Bn-DTPA as the host-linker moiety.
Figure 6. Synthesis of the small molecule CA IX imaging agent 99mTc-PS and control compound Re–PS.
